ADVERTISEMENT

Dyslipidaemia risks rise after COVID-19

Jenny Blair, MD   |   Clinical Summary   |   13 January 2023
ADVERTISEMENT

As do rates of lipid-lowering medication use.

Takeaway

  • New-onset dyslipidaemia, including abnormal triglycerides and cholesterol requiring lipid-lowering medications, is a frequent postacute phase consequence of SARS-CoV-2 infection.
  • This study adds to growing evidence that people who survive COVID-19 are at higher risk for cardiometabolic disorders.

Why this matters

  • Disturbances to...

          

Topic Challenges

left
right